Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
08:15am, Thursday, 26'th Sep 2024
Iovance Biotherapeutics is laying the groundwork to start realizing lots of revenue. It also has a lot of work in progress to increase the number of patients it can help.
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
06:29am, Monday, 16'th Sep 2024
Iovance Biotherapeutics will take some time to become profitable. It will probably see its medicine approved in more places before that happens.
This Is the Biggest Risk With Iovance Biotherapeutics Stock
09:30am, Friday, 06'th Sep 2024
Iovance Biotherapeutics obtained accelerated approval for its cell therapy, Amtagvi, earlier this year. The company has begun rolling it out, and it presents a big opportunity for the business.
Iovance Biotherapeutics to Present at Upcoming Conferences
05:00pm, Tuesday, 03'rd Sep 2024
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
3 Monster Biotech Stocks to Buy Before 2025
06:15pm, Monday, 02'nd Sep 2024
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
04:36am, Tuesday, 27'th Aug 2024
The Food and Drug Administration approved Iovance Biotherapeutics' first therapy, Amtagvi, in February. Amtagvi is a complicated treatment made from immune cells found in tumor biopsies.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:00pm, Friday, 16'th Aug 2024
SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
07:15am, Wednesday, 14'th Aug 2024
Iovance Biotherapeutics is now selling its first cell therapy, Amtagvi. Amtagvi requires significant logistical and manufacturing coordination.
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
09:00am, Sunday, 11'th Aug 2024
Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in
Why Iovance Biotherapeutics Shares Are Soaring Today
12:23pm, Friday, 09'th Aug 2024
Although only approved in February, Iovance's Amtagvi is already selling well. The drug in question also has potential as a treatment for several other types of cancer.
Why Is Iovance Bio (IOVA) Stock Up 18% Today?
12:20pm, Friday, 09'th Aug 2024
Iovance Biotherapeutics (NASDAQ: IOVA ) stock is taking a beating on Friday after the biotechnology company announced its earnings for the second quarter of the year. Iovance Biotherapeutics starts
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
11:20am, Friday, 09'th Aug 2024
Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
10:31am, Friday, 09'th Aug 2024
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
08:32pm, Thursday, 08'th Aug 2024
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
06:31pm, Thursday, 08'th Aug 2024
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.47 per share a year ago.
